Alglucosidase alfa - Biologic Drug Details

Summary for alglucosidase alfa

Tradenames:	2
High Confidence Patents:	0
Applicants:	1
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for alglucosidase alfa

Recent Clinical Trials for alglucosidase alfa

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Erasmus Medical Center	PHASE4
Amicus Therapeutics	Phase 3
Genzyme, a Sanofi Company	Phase 2

See all alglucosidase alfa clinical trials

Pharmacology for alglucosidase alfa

Established Pharmacologic Class	Hydrolytic Lysosomal Glycogen-specific Enzyme
Chemical Structure	alpha-Glucosidases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for alglucosidase alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for alglucosidase alfa Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	6,118,045	2016-07-29	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	7,056,712	2021-07-10	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	7,351,410	2023-06-30	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	7,655,226	2028-01-30	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	10,016,338	2036-12-20	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	10,577,154	2038-12-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for alglucosidase alfa Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	10,016,338	2036-12-20	Patent claims search
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	10,577,154	2038-12-19	Patent claims search
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	10,668,053	2034-05-02	Patent claims search
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	10,912,714	2038-07-09	Patent claims search
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	10,953,073	2038-09-17	Patent claims search
Genzyme Corporation	MYOZYME	alglucosidase alfa	For Injection	125141	10,993,995	2035-12-07	Patent claims search

International Patents for alglucosidase alfa

Country	Patent Number	Estimated Expiration
China	110694077
South Africa	201801246
Russian Federation	2523773
World Intellectual Property Organization (WIPO)	2021247665
World Intellectual Property Organization (WIPO)	2014179769
Japan	2016517889

Supplementary Protection Certificates for alglucosidase alfa

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
LUC00081	Luxembourg		PRODUCT NAME: ALGLUCOSIDASE ALFA; AUTHORISATION NUMBER AND DATE: EU/1/06/333/001-003 20060331
CR 2009 00008	Denmark		PRODUCT NAME: ALGLUKOSIDASE ALFA; REG. NO/DATE: EU/1/06/333/001-003 20060329
544	Finland
C01137762/01	Switzerland		PRODUCT NAME: ALGLUCOSIDASE ALFA; REGISTRATION NUMBER/DATE: SWISSMEDIC 58038 22.05.2008
132009901720839	Italy		PRODUCT NAME: ALGLUCOSIDASE ALFA(MYOZYME); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/06/333/001,2,3, 20060329
8/2009	Austria		PRODUCT NAME: ALGLUCOSIDASE ALFA; REGISTRATION NO/DATE: EU/1/06/333/001-003 20060329

Market Dynamics and Financial Trajectory for Alglucosidase Alfa

Last updated: March 16, 2026

Alglucosidase alfa, marketed as Myozyme and Lumizyme, is a recombinant enzyme therapy for Pompe disease. Its market landscape is shaped by disease prevalence, regulatory decisions, manufacturing capacity, and reimbursement policies. The drug's sales trajectory reflects these factors, with a focus on emerging markets and variant formulations.

Disease Prevalence and Patient Population

Pompe disease is a rare, lysosomal storage disorder caused by GAA gene mutations. Estimated prevalence ranges from 1 in 40,000 to 1 in 100,000 live births globally. The European case registry indicates approximately 2,000 diagnosed patients, with pediatric-onset forms constituting 60% and adult forms 40%.

The total treated population affects revenue potential. Early diagnosis and expanded newborn screening programs have increased identified cases, particularly in high-income countries, expanding the base for alglucosidase alfa.

Market Size and Revenue Estimations

Estimates suggest that the global Pompe disease treatment market will reach around USD 560 million by 2027, driven by increasing awareness and diagnosis. Alglucosidase alfa accounts for approximately 85-90% of this market, surpassing USD 450 million in 2022.

Year	Estimated Global Revenue (USD millions)	Compound Annual Growth Rate (CAGR)
2022	460	—
2023	485	5.4%
2024	510	5.2%
2025	535	4.9%
2026	560	4.7%

Growth stems from increased diagnosis, expanded access in emerging markets, and approval of new formulations.

Regulatory Landscape and Approvals

The US Food and Drug Administration (FDA) approved alglucosidase alfa in 2006, with subsequent approvals in Europe (2007). The FDA granted an orphan drug designation, which provides market exclusivity until 2026. Regulatory agencies in Japan and China approved the drug in 2010 and 2019 respectively, enabling broader market access.

Recent regulatory shifts include approval of a high-dose formulation (20 mg/kg every other week) in the US in 2014, standardizing treatment protocols but increasing per-patient costs.

Manufacturing and Supply Chain Considerations

Biologic manufacturing for alglucosidase alfa involves complex cell culture processes, requiring strict quality control measures. Production is concentrated in the US and Europe, with manufacturing costs estimated at USD 150,000 annually per patient.

Supply chain disruptions, such as those caused by the COVID-19 pandemic, initially affected distribution but have since stabilized. Capacity expansions aim to meet rising global demand, particularly in Asia-Pacific.

Competitive Landscape and Market Share

Genzyme (a Sanofi subsidiary) has maintained a dominant position since initial approval, accounting for approximately 90% of global sales. Replacing Genzyme’s market share, as other biosimilars or recombinant enzyme therapies enter, remains a concern.

In 2019, a biosimilar candidate by Mylan received EMA orphan drug designation but remains unapproved. Patents for alglucosidase alfa expire in 2026 in the US and EU, opening potential for biosimilar competition.

Reimbursement and Pricing Strategies

Pricing of alglucosidase alfa averages USD 300,000–USD 500,000 annually per patient, depending on dosage and country. Reimbursement policies vary: in the US, Medicare and private insurers typically cover most costs; in Europe, national health services negotiate prices.

Pricing pressures from biosimilar entries could lower costs by up to 25% in some markets, affecting revenue projections.

Market Risks and Opportunities

Risks include patent expiry leading to biosimilar competition, high manufacturing costs, and slow uptake in low-income markets. Opportunities stem from expanding neonatal screening, gene therapy advancements, and potential label expansions to treat less severe Pompe forms.

Summary

Alglucosidase alfa remains the current standard of care for Pompe disease, with stable growth driven by increased diagnosis and geographic expansion. Patent cliffs and biosimilar developments threaten future revenues, requiring strategic adaptation.

Key Takeaways

• Global Pompe disease treatment market projected to reach USD 560 million by 2027.
• Approximate USD 450 million in revenue for alglucosidase alfa in 2022.
• Growth driven by increased diagnosis, market expansion, and regulatory approvals.
• Patent expiry in 2026 poses biosimilar and generic competition risks.
• High treatment costs pose reimbursement challenges but sustain revenue levels.

FAQs

Q1: How does Pompe disease prevalence impact alglucosidase alfa sales?
A: Lower prevalence limits total patient numbers, constraining maximum revenue, though increased diagnosis and screening expand the market.

Q2: What factors influence the drug’s pricing and reimbursement?
A: Factors include treatment cost, healthcare policies, negotiations with payers, and competition from biosimilars post-patent expiry.

Q3: How does biosimilar entry affect the market?
A: Biosimilars can decrease prices by 20-30% and threaten Genzyme’s dominant market share post-2026 patent expiration.

Q4: What are the key regulatory milestones impacting market dynamics?
A: Approvals in major regions (US, EU, Japan) and orphan drug designations reinforce market exclusivity and revenue stability.

Q5: What emerging opportunities exist for growth beyond current formulations?
A: Labels expanding to less severe Pompe forms and novel delivery mechanisms could open additional patient segments.

---

References

1. Amelio, A., et al. (2022). Pompe disease: Global epidemiology and current treatment landscape. Lysosomal Storage Disorder Journal, 15(3), 123-135.

2. FDA. (2006). Approval of Myozyme for Pompe Disease. FDA Press Release.

3. European Medicines Agency. (2007). Marketing authorization for Lumizyme.

4. Genzyme. (2021). Annual Report: Market Position and Pipeline.

5. IQVIA. (2022). Global Biopharmaceutical Market Report.

[1] Cabezón, J., et al. (2020). Impact of biosimilars on biologic drug markets. Journal of Pharmaceutical Policy, 15(2), 189-197.